Strangvac has been in development for over 25 years and Dechra says it's the first and only intramuscular vaccine to help protect against strangles.
Strangvac contains recombinant proteins CCE, Eq85 and IdeE from Streptococcus equi and has DIVA (Differentiating Infected from Vaccinated Animals) capability.
The vaccine contains no live bacteria or bacterial DNA, so will not trigger positive culture or PCR tests.
In trials the new vaccine protected more than 94% of horses1.
Dechra says it reduces the clinical signs of strangles including a high temperature, coughing, inappetence, difficulty swallowing and changes in demeanour, while also reducing the number of lymph node abscesses.
Strangvac can be given to foals from five months of age and two injections should be given at a four-week interval.
Horses at high risk of Streptococcus equi infection, such as those in livery, should be revaccinated after two months.
Based on measured antibody titres, immunological memory was found in horses following repeated vaccination six months after primary vaccination.
Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, said: “Strangvac is a ground-breaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”
https://www.dechra.co.uk/equine/vaccines
Zoetis Business Consulting has released figures showing that Profit Solver, its financial analysis tool, has delivered an average EBITDA (earnings before interest, taxes, depreciation and amortization) growth of 36% for the 28 UK practices that have used the new service since its launch.
Profit Solver was first launched in the USA, where the company says more than 300 practices have now benefited from the service.
Zoetis says that traditionally, veterinary practices have set their prices by simply adding a set mark-up, without knowing which services make a profit or loss and without understanding exactly how overall practice profit is being generated.
Profit Solver instead uses the practice’s own data to calculate the exact cost for the 130 most commonly performed veterinary services, representing 90% of the revenue generated by the practice. It then combines labour, inventory and equipment costs with time-and-motion studies for each service, and assesses the variance between cost and price to reveal profit or loss.
By using a collection of cost data, which staff perform which part of the procedure, how long the procedure takes and what equipment and materials are used, Profit Solver calculates the correct pricing to both cover costs and deliver a pre-determined profit margin.
Implementing Profit Solver is done with a Zoetis business consultant who guides the practice through the process, from data collection to examining the time-and-motion studies. They discuss the level of profitability the practice needs to deliver and help analyse prices to achieve this goal whilst preserving the price-point of highly competitive services and covering all the practice’s costs.
Ian Camm, Group Director of B&W Equine Vets in Gloucestershire heard about Profit Solver from a vet in a neighbouring practice who was impressed with how it had helped his business. Ian discussed Profit Solver with his Zoetis account manager and booked an appointment with Zoetis Business Consultant Anthea Pike who has helped him implement the software across B&W Equine Group.
He said: "Initially I was concerned that Profit Solver would suggest we put prices up where we felt that we would not be able to - people shop around for their veterinary services these days and many services are very price sensitive. The first stage in the process addressed this by looking at our figures, calculating the cost price for each procedure and then, by comparing with our fees charged, identified where we were losing money. The big question was whether we would be comfortable to increase our fees on loss-making procedures. The beauty of the system was that by looking at a large number of procedures which were done frequently, very small increases in fee would total to a significant improvement in the bottom line.
"The software has made us recognise where the real costs are and how to address these areas accordingly, for example we have identified that current stud packages are not profitable. One of the problems in arriving at true costs is the difficulty in accurately allocating time to various procedures when several different vets are involved or an expensive scanner is used, which can have a significant impact on the results. It’s early days, but I can already see the difference that Profit Solver could make to our bottom line and wouldn’t hesitate to recommend it providing the practice is prepared to make changes in light of the results. We are looking at improving our bottom line by a six figure sum over a 12 month period with what we hope, will be hardly noticeable price rises.”
For further information visit www.zoetis.co.uk/businessconsulting.
The first charge was that in April 2016, having examined a horse named Alfie on behalf of his owner, Mr Villar gave an opinion to the potential buyers but failed to make it clear that he had not undertaken a pre-purchase examination; failed to declare to the buyer that he had a conflict of interest with regard to the owner; and, failed to explain the pre-purchase examination process to the buyers.
The second charge was that, in July 2016, during a telephone conversation with the buyer, Mr Villar was dishonest and failed to provide clear and accurate information because he told the buyers that he had only been asked to trot Alfie to check he was sound when he had, in fact, carried out a more substantial examination.
The third charge was that Mr Villar had offered to either the owner or the buyer, or both, that he would prepare a veterinary insurance certificate in relation to Alfie when he knew he did not have sufficient records (eg the microchip or passport number) to do so.
The fourth charge was that Mr Villar failed to respond adequately to communications from the buyers about Alfie.
The Committee found that Mr Villar had not in fact carried out a pre purchase examination (“PPE”) and referred to guidance from the British Equine Veterinary Association which identified that pre-purchase examinations are carried out on behalf of buyers. It noted that in this case, Mr Villar had undertaken an examination on behalf of the owner. Accordingly, it did not find that Mr Villar had failed to explain the PPE process to the potential buyers.
However, the Committee did find that Mr Villar had failed to declare that he had a conflict of interest in regards to Alfie’s owner. The Committee said that Mr Villar should have told the buyer that he had been acting on behalf of the owner and was not a neutral party in the potential sale.
The Committee found all aspects of the second charge not proven, on the basis that it was not satisfied so as to be sure that Mr Villar had told the potential buyers that he had only been asked to trot Alfie and check that he was sound.
The Committee found all aspects of the third charge proven on the basis that, in an email sent to the College in March 2016, Mr Villar admitted that he did not have the sufficient records to prepare a veterinary insurance certificate.
The Committee found the fourth charge not proven on the basis that the buyers were not his clients. The Committee therefore concluded that he had no obligation to respond to them, and indeed could not do so in certain respects in order to preserve the confidentiality of his client.
The Committee then determined that the charges found proven, when taken individually or in combination, did not amount to serious professional misconduct.
Ian Green, chairing the Committee and speaking on its behalf, said: "The following mitigating factors were present in this case: the circumstances of the incident, the fact that there was no premeditation, the fact that he was requested by his client to advance an opinion to [the buyers] concerning Alfie and that his ill judgement was on the spur of the moment and the fact that he had no financial gain. These are all important factors. Likewise, the fact that he did not know that the [buyers] regarded him as their pre-purchase examination vet is an important matter.
"The respondent’s conduct was clearly against the principles of behaviour articulated by Mr Morley [who acted as an expert witness for the College] in his expert report and in his evidence. Nevertheless, the Committee does not find that in the particular circumstances of this case, namely being asked to speak to a potential purchaser without warning and without being made aware of the contractual arrangements which had been made between the respondent and [the owner], the respondent should not properly be the subject of a finding of disgraceful conduct in a professional respect."
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
References
Following last year's campaign, Merial commissioned a survey to learn more about how horse owners seek and receive information about the wider aspects of preventative healthcare, and in particular about the relationship with their veterinary practice.
In the survey of 455 horse owners, which was carried out by CMI Research, 78% said their veterinary surgeon was the most important source of information. The next most important influencers were yard managers/grooms at just 22%.
Louise Radford MRCVS from Merial said: "We wanted to learn more about client education and the opportunities for practices to get more from their client relationships, including vaccination and booster uptake. However we hadn’t estimated just how much horse owners rely on their vet for information!"
"However there appears to be a significant gap between vets as a source of information, and their client’s purchasing habits. Health plans are a great example of the potential for improved compliance, with benefits to the horse, client and practice. Yard health plans present an opportunity to increase booster uptake and also to include animals that might not otherwise be vaccinated.
"Of those horse owners and grooms surveyed who did not vaccinate some or all of their horses, their reasons included horses that never leave the yard, or are old, young, or do not interact with other horses. Yet we know that horses that don’t travel are still at risk of equine flu, as virus can travel up to a mile as an aerosol on the wind, in addition to being carried on objects such as buckets and tack.
"So as the key influencers on preventative healthcare, there is much that practices can do to further engage with clients to increase uptake of products and services, improve client loyalty, and ultimately boost the practice business."
For more information on Equine Flu Awareness Month- 2017, including client materials and video content, visit www.equinefluawareness.com
The 2020 OV Conference will offer up to 25 hours of CPD with lectures, workshops and Q&A sessions from world-class speakers in streams covering small animals, farm animals and equines. There will also be exclusive offers from industry sponsors and online networking opportunities.
The OV Conference provides an opportunity for OVs to discuss current topics of interest and recent developments in their work. Themes this year will include notifiable diseases, biosecurity and disease control, and export certification.
In addition to the live lectures, delegates will be able to view recordings of all the sessions on-demand for three months following the conference. The CPD on offer counts towards OV revalidation qualifications with the event open to all vets, as well as animal health paraprofessionals, nurses and practice managers.
David Babington MRCVS, Business Development Director at Improve International, said: "Moving the OV Conference online has given us an opportunity to harness the technology we use regularly in all of our veterinary training to bring OVs an exceptional but affordable CPD experience.
"Our excellent speakers are looking forward to sharing the latest updates in all aspects of OV work with our delegates and to discussing the challenges ahead, particularly in the light of the COVID-19 pandemic and with the UK moving inexorably towards leaving the EU at the end of the year.
"We’re looking forward to meeting our delegates old and new online at the OV Conference in September.”
The full programme and tickets are now available from https://officialvet.com
The first 150 tickets will get an ‘Early Bird’ 25% discount from £160 to £120+ VAT using the code UK.OV.EARLYBIRD.
All bar one of the suspended drugs contain the NSAID flunixin. The other affected drug is the antibiotic, Tribrissen:
Allevinix 50 mg/ml Solution for Injection for Cattle, Pigs and Horses (Ceva Animal Health)
Cronyxin Injection, 5% w/v Solution for Injection, for cattle and horses (Cross Vetpharm Group Ltd)
Finadyne 50 mg/ml Solution for Injection for cattle, pigs and horses (Intervet UK Ltd)
Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Meflosyl 5% Solution for Injection for horses and cattle (Zoetis UK Limited)
Norixin 5% Solution for Injection for cattle and horses (Norbrook Laboratories Limited)
Pyroflam 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Tribrissen 48% Suspension for Injection for horses, pigs and cattle (Intervet UK Ltd)
The British Equine Veterinary Association says that the decision to suspend the drugs was taken without consultation with the veterinary profession, and is urging the VMD to overturn the suspension in horses not destined for the human food chain, to reduce the potential impact on equine welfare.
Jonathan Pycock, BEVA president said: "BEVA is fully supportive of all attempts to promote food safety, however flunixin is widely viewed as the gold-standard pain killer in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic.
"BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue. BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”
The ten-minute online survey aims to gather a snapshot of horse health over the period of a week.
The results help to identify trends in endemic equine diseases and help the Blue Cross steer equine awareness, education and research.
This year the survey includes some welfare questions to help guide knowledge in response to what the charity calls 'the UK’s horse welfare crisis'.
The National Equine Health Survey is run by the Blue Cross in partnership with the British Equine Veterinary Association. Dodson and Horrell is helping to cover the costs of running the scheme.
Supporters of the survey include the British Horse Society, Horse Trust, Redwings and the Pony Club.
Medal-winning riders Mary and Emily King, and Yazmin Pinchen (pictured right) also support the survey.
Visit www.bluecross.org.uk/NEHS or email NEHS@bluecross.org.uk to register and take part, which carries the chance of winning prizes including Star Lister Clippers, a Lister Adagio Trimmer and some Burford Ariat boots.
Participation in this year’s survey was similar to previous years with 5,235 people taking part and returning records for 15,433 horses. Most horses were kept in livery or a private yard and used for leisure and hacking and the majority within the age range of 5 to 10 years.
A broad variety of breeds were represented, including natives, thoroughbred types and warmbloods.
59% of horses were recorded as healthy and 41% with one or more health problems, compared to 62% and 38% respectively in 2016.
The top five disease syndromes recorded this year were:
Of the 5.5% of horses recorded with back problems 26% were also showing signs of lameness. While the details of the results do not confirm that the two are necessarily connected, these findings reflect the outcome of recent studies conducted by Dr Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust.
Sue said: "It is a common observation that horses with lameness stiffen the back as a protective mechanism and develop muscle pain which may be misinterpreted as a primary back problem. We have shown objectively that abolition of lameness by diagnostic analgesia results in an immediate increase in range of motion of the back. The current data supports this close relationship between lameness and back pain."
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
The manufacturer has identified that there is a potential for decreased levels of the preservative Chlorobutanol hemihydrate in the following batch: J2101-03 Expiry 11/2018.
Oxytobel is distributed in the UK by Bimeda UK. Veterinary practices that have purchased this batch number should contact Bimeda to arrange collection.
Any queries in relation to return of the product or credit for the product returned should be addressed to Kay Cowton, Bimeda UK Sales on 01248 725400 or email: uksales@bimeda.com
For further information on the recall please contact Bela-pharm GmbH & Co.KG: +49 (0) 44 41 873 294.
Merial has announced the UK launch of updated ProteqFlu, the first and only EI vaccine in Europe to contain a clade 2 strain.
The company says the new vaccine is also the only one that is fully compliant with the latest 2014 OIE recommended EIV strains.
Louise Radford MRCVS from Merial said: "The launch marks the UK's first and only fully updated equine flu vaccine that contains both a Clade 1 and Clade 2 antigen which includes protection against the latest Florida Clade 2 strain, Richmond 07. This is a significant step for horse health, and the equine industry as a whole."
Hervé Poulet, Merial's head of BioDevelopment and BioResearch said: "Merial has developed strong and unique expertise in the development of non-replicative recombinant canarypox virus-vectored vaccines for various species and diseases.
"For the development of ProteqFlu, our non-replicative recombinant canarypox vector expressing the EI virus haemagglutinin (HA) is used because of its ability to induce a strong cellular immunity which is an essential component in protecting against this highly contagious disease."
Louise added: "ProteqFlu has also demonstrated its success and efficacy in real outbreaks, particularly during the last major outbreak, in Australia in 2007. ProteqFlu was the only vaccine chosen for the eradication programme."
Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.
The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.
Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK. Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.
Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.
We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives. While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world. We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."
Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation. Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”
The survey of 50 vets carried out in May this year1 found that only half of them are recommending strangles vaccination to their clients.
They also felt that horse owners could be doing more to combat the disease.
Less than half of vets questioned believed that yards and premises operated good biosecurity measures prior to a strangles outbreak, yet 85% brought in more stringent biosecurity after an outbreak, when it was too late.
Dechra says that vets and horse owners can help combat the estimated 300 outbreaks of strangles each year with the following steps:
Sara Barker BVSc CertAVP(EM) MRCVS, equine field support manager at Dechra, said: “Strangles is one of the most common equine infectious diseases both in the UK and worldwide and a multi-factor approach is key to tackling the disease.
"Strangles vaccination is recommended, alongside good biosecurity, quarantine measures and regular temperature checking.
"By working together, vets and horse owners can help to keep horses healthy and prevent the spread of strangles.”
Reference
The Waltham Equine Studies Group has announced the results of two pieces of research designed to improve understanding of the best nutritional support for older horses, whether they are healthy or diagnosed with Pituitary Pars Intermedia Dysfunction (PPID or Cushing's).
The first study: A comparison of nutrient digestibility between adult and aged horses, conducted by the Department of Large Animal clinical Sciences and Animal Science, Michigan State University and The Waltham Equine Studies Group, confirmed (in contrast to earlier work) that there was no difference in digestibility between healthy adult and aged horses when fed a variety of common equine diets.1
In the second study: Characterisation of the faecal bacterial community in adult and elderly horses fed a high fibre high oil or high starch diet, the Institute of Biological Environmental and Rural Sciences, Aberystwyth University, The Waltham Equine Studies Group and Michigan State University used the same horses as the previous study but this time looked at their gut microflora. The results showed that although no significant differences in individual species of bacteria were found, ageing was, however, associated with a reduction in bacterial diversity. This, say the authors, may in part explain why older animals can be at increased risk of intestinal disturbances.2
An abstract that summarised part of the Waltham Equine Studies Group's work on the effect of additional supplementation on aged horses with and without PPID was presented at the 2nd Dorothy Havermeyer Geriatric Workshop in the USA last November.3 This work, carried out in conjunction with Dr Amanda Adams at the University of Kentucky showed that age is key in influencing inflammation and metabolism rather than whether the horse is PPID positive or not.
Professor Pat Harris, head of the Waltham Equine Studies Group, said: "For the parameters we monitored, the research showed that it is being old that is the issue, rather than having PPID."
Clare Barfoot RNutr and the research and development manager at Spillers said: “This should give us a better understanding of the effects of diet and age on metabolism in order to determine optimal nutrition for the senior horse. Preliminary work suggests that this new research may change the way we think of feeding the older horse. Waltham’s work continues to ensure that Spillers feeds remain at the forefront of equine nutrition, for the better health of horses everywhere.”
Rominervin contains 10 mg/ml romifidine hydrochloride, equivalent to 8.76 mg romifidine, presented in a 20 ml vial.
It can be used as a sedative to facilitate handling, examination, minor surgical interventions and minor procedures or as a premedication prior to administration of injectable or inhalation anaesthetics.
Rominervin can also be used in combination with synthetic opiates such as butorphanol to provide deeper sedation or analgesia.
Dechra Brand Manager Emma Jennings said: "Rominervin is highly effective as it has a longer duration of action than other alpha-2 agonists1. It starts to work within one to two minutes with maximum sedation achieved between five and 10 minutes.
"It is yet another valuable addition in our equine anaesthesia and analgesia range that has been designed to provide vets with the therapies they need to operate successfully in day-to-day practice."
Rominervin can be used in conjunction with Dechra’s equine anaesthesia and analgesia app, designed to help veterinary professionals choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates.
For more information visit: www.dechra.co.uk/products/equine
The aim of the week is to focus equine practices on ‘Taking care of the small things that make a big difference’ with a toolkit of resources designed to help them promote their businesses and educate and promote the benefits of preventative healthcare.
Peter Young, MSD Equine Business Manager said: "This year’s Horse Health Week has been created to focus on the small things we can all do to help keep our nation’s horses happy and healthy. We are encouraging equine vets to get involved and engage with their clients throughout the week with the support of our toolkit. This celebration of Britain’s horses and the things we can do to improve their health is a positive opportunity for vets to build client loyalty and attract new clients. I urge practices to do as little or as much as they can, but I urge them to do something!"
Horse Health Week is supported with a range of materials for both practices and clients, along with social media content, which vets can obtain on a USB stick from their MSD Animal Health Equine representative.
The toolkit includes a series of five animations – one for each day of the week. They each cover a different topic including; horse connections, the importance of hand washing, equipment at shows, isolation and vaccination. There is also a social media campaign for practices to run called #BonVoyageBuzz, and a survey that will gather the views of horse owners on preventative healthcare.
For full details talk to your MSD Animal Health Account Manager, call MSD on 01908 685685 or refer to www.healthyhorses.co.uk/horse-week.
Until the arrival of Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), radiographs were the only feasible option. More recently, the availability of bigger, wider and more adaptable scanners has allowed horses to be examined in a standing position, significantly improving diagnostic and treatment strategies and avoiding the need for general anaesthetic.
Against this background the collection considers the advantages of cutting-edge modalities and draws comparisons with more readily available tools such as radiography.
Given the increase in use of CT in horses and the contamination hazards faced particularly by horse handlers, two practical articles in the collection describe the role of equine head CT, how to set up standing equine CT and the radiation exposure risks.1,2
The most revolutionary recent advance in diagnostic imaging for dental disease in horses is CT. However, a study of horses with diseased mandibular cheek teeth found that while CT is useful to identify defects in the bone and tooth it is far less useful for the identification of inflammation and tissue destruction which is far better served by MRI.3
The structure of the equine head is complex and subject to great variation so several articles focus on practical anatomy and interpretation of radiographs of this region.4.5 Advanced diagnostic techniques are helping with clinical and surgical approaches to problems with the equine head. The sphenopalatine sinus is challenging to assess radiographically because of its tricky position but CT can help overcome this obstacle. One of the studies describes how CT can help unravel the pathology of various equine sinonasal tumours. Other articles cover less common pathological conditions including the historical, clinical, diagnostic imaging findings and outcomes of five horses with pneumocephalus. 6,7,8
Practitioners recognise MRI as the gold standard for neurologic imaging because of the excellent soft tissue detail but the size of horses and the size of scanners makes it a challenge to use. An additional constraint is the longer acquisition time compared to CT. Notwithstanding these limitations three studies in the collection display the various benefits of using MRI for the spine and neck, including the evaluation of 84 equine head disorders, the diagnosis of cervical stenotic myelopathy, and the assessment of two foals with closed head trauma.9,10,11,12
Despite the significant advances in imaging, the horse’s back is still defying conventional systems, primarily because of its size, concludes a spinal evaluation article. New technologies such as robotic fluoroscopy and cone-beam CT, may provide a cross-sectional method to evaluate the equine spine, but for now radiographs are still better to help evaluate findings of spinous process impingement seen on scintigraphy. The take home message here is that the wide variety of abnormalities seen on scintigraphy and radiography in horses with and without back pain makes a diagnosis more likely to be achieved by physical examination rather than the imaging findings.13
Anthony Pease, associate editor of the EVJ said: "Advanced imaging is still in its infancy with sequences still being developed to help optimise the time and detail needed for diagnosing complex musculoskeletal and neurologic disorders. Continued research in a controlled environment and comparing to histopathology will allow clinicians to further their knowledge and understanding of the CT and MRI findings in the equine patients."
Intervet/Schering-Plough Animal Health has announced that it is to sponsor the Equine Business Management Strategies (EBMS) program, a targeted business education program developed for equine veterinary surgeons and practice professionals.
According the company, this 5-day course has proven very successful in the United States. It had its European kick-off in Amsterdam on August 22, 2010, where a group of almost forty equine practitioners from North America and Europe gathered to discuss and learn how to apply business principles in their day-to-day work. The program was chaired by Dr. Joop Loomans, an equine veterinary surgeon responsible for equine business management education at the Department of Equine Sciences of the Veterinary Faculty of Utrecht University (The Netherlands).
Course participants worked with international specialists on strategic planning, benchmarking, branding and change management to create strategic plans to implement at their practices, and to share their knowledge, experience and ideas.
Intervet/Schering Plough says the launch of Equine Business Management Strategies program exceeded expectations of participants, sponsor and organizers. The chance to look at the day-to-day practice from a different angle and to learn about things like benchmarking exercises, revenue analysis and branding was highly appreciated. Participant Jeremy Mantell from Liphook Equine Hospital in the UK said: "The EBMS has given me a clearer understanding of what I need to change and develop in my practice."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering-Plough Animal Health said: "We believe that running an equine practice is not based solely on technical and scientific skills but also on effective practice management. That is why our company has decided to support this initiative. Intervet/Schering-Plough Animal Health also continues its custom of providing not only innovating products, but also new, value-added services to strengthen its bond with veterinarians."
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
Apparently, there were over 100 times more recorded outbreaks of equine flu across the UK in 2019 than the year before1, and numerous equestrian events were cancelled as a result.
The company says that despite this, as of 2019, only about half of all UK horses are vaccinated2.
Blaise Scott-Morris MRCVS, Equine Marketing and Technical Manager at MSD Animal Health said: "Last year’s outbreaks of equine flu rocked the equine world, raising important animal welfare issues and costing the racing industry millions.
"Furthermore, they highlighted the need for good preventative healthcare and, in particular, vaccination. It’s vital that more owners are encouraged to vaccinate and those that already have, to keep up with their annual vaccinations and health checks so we don’t experience the same suffering again."
MSD's campaign invites horse owners to join the movement to #fightequineflu, and there is a range of materials to help practices promote the campaign and encourage clients to talk about vaccination and preventative healthcare, including an educational infographic poster, a social media pack and new resources on the Chameleon appointment reminder system.
MSD will itself be promoting the campaign on social media (Facebook: @Keeping Britains Horses Healthy, Instagram: @KeepingHorsesHealthy), and through partnerships with consumer channels such as Horse and Country TV.
There is also a new information resource online at www.kbhh.co.uk/achoo, which offers horse owners links to a range of other educational preventative health materials and horse care advice.
To request your Fight Equine Flu practice pack, speak to your MSD account manager.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
BCF Technology has launched a competition to win a top of the range digital radiography system from its Cuattro range for 6 months.
To enter the competition, you need to record a short video (up to 2 minutes) explaining how the DR system would transform your imaging function. BCF is asking entrants to be as creative as possible as the voting will be open to the public. The company will pick a shortlist of finalists and then invite the public to vote for a winner on its Facebook page and website.
The competition is open to both small animal and equine vets, for the following systems:
Sarah O'Grady from BCF said: "Having a Cuattro DR system could make a huge difference to either a small animal or an equine practice. For a small animal vet practice that doesn't currently have a DR system, they will love the difference it makes to X-ray studies. Diagnostic images are produced in seconds and re-takes are almost non-existent. A Wireless Slate 3+ can greatly improve the ease of in-stable operations and procedures. With the removal of wires, these procedures run much smoother. You will also be surprised by the improvement in image quality."
The closing date for the competition is 30th November 2013.
To enter your video:
The winner will be required to arrange insurance for the system during the time they have the system. Full terms and conditions can be found on the BCF website.
To find out more visit the BCF website or Facebook page or call +44 (0)1506 460 023.